Drug pricing reform talks with US government lack clarity, industry executives say
June 10 (Reuters) – Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly (LLY.N), opens new tab and Merck (MRK.N), opens new tab said at an industry conference on Tuesday.
President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay.
